Cara Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Tvardi Therapeutics

05/03/2024 23:27

* Cara Therapeutics Inc  CARA.OQ  reported a quarterly
adjusted
loss of 59 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -56 cents.  The mean expectation of six analysts for the
quarter was for a loss of 41 cents per share. Wall Street
expected results to range from -60 cents to 19 cents per share.
    * Revenue fell 7.9% to $3.00 million from a year ago;
analysts
expected $9.42 million. 
    * Cara Therapeutics Inc's reported EPS for the quarter was a
loss
of 59 cents​.
    * The company reported a quarterly loss of $32.34 million.
    * Cara Therapeutics Inc shares had risen by 34.6% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Cara Therapeutics
Inc is $5.00 
This summary was machine generated from LSEG data March 5 at
11:27 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.41          -0.59          Missed
 Sep. 30 2023      -0.52          -0.52          Met
 Jun. 30 2023      -0.54          -0.58          Missed
 Mar. 31 2023      -0.52          -0.49          Beat